5.65

0.71% 0.04

Kazia Therapeutics Limited Adr (KZIA)

Overview News Price History Option Chain Discussions Forecast Stock Split

Kazia Therapeutics Limited Adr stock is traded at $5.65, with a volume of 7,463. It is up +0.71% in the last 24 hours and up +0.61% over the past month. Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.

Previous Close:

$5.61

Open:

$5.63

24h Volume:

7,463

Relative Volume:

0.05

Market Cap:

$19.46M

Revenue:

Net Income/Loss:

$-13.52M

P/E Ratio:

-7.6351

EPS:

-0.74

Net Cash Flow:

$-10.03M

1W Performance:

+7.21%

1M Performance:

+0.61%

6M Performance:

+100.50%

1Y Performance:

-18.12%

1-Day Range:

$5.50

$5.8731

1-Week Range:

$4.30

$6.01

52-Week Range:

$1.866

$15.80

Kazia Therapeutics Limited Adr Stock (KZIA) Company Profile

Name

Kazia Therapeutics Limited Adr

Sector

Healthcare (1195)

Industry

Biotechnology (683)

Phone

01161298780088

Address

140 WICKS RD, NEW SOUTH WALES 2113, NSW

Employee

Twitter

@KaziaTx

Next Earnings Date

2024-11-04

Latest SEC Filings

KZIA's Discussions on Twitter

Compare KZIA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KZIA	5.7025	19.46M	0	-13.52M	-10.03M	-0.74
VRTX	448.26	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	744.88	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	592.97	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	248.80	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	103.82	24.49B	3.30B	-501.07M	1.03B	11.54

Kazia Therapeutics Limited Adr Stock (KZIA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-14-21	Initiated	Maxim Group	Buy
Jan-05-21	Initiated	H.C. Wainwright	Buy

Kazia Therapeutics Limited Adr Stock (KZIA) Latest News

Nov 12, 2024

SEC Form 424B3 filed by Kazia Therapeutics Limited - Quantisnow

Nov 12, 2024

Nov 04, 2024

Kazia sets FDA meeting for glioblastoma drug pathway - Investing.com India

Nov 04, 2024

Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme - StockTitan

Nov 04, 2024

Oct 30, 2024

U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.65% - MSN

Oct 30, 2024

Oct 29, 2024

Leptomeningeal Metastases Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Y-mAbs Therapeutics, Plus Therapeutics, AngioChem, AstraZeneca - The Globe and Mail

Oct 29, 2024

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.65% - MSN

Oct 29, 2024

Oct 28, 2024

Upcoming Stock Splits This Week (October 28 to November 1) – Stay Invested - Nasdaq

Oct 28, 2024

Oct 16, 2024

Ratios in Focus: Analyzing Kazia Therapeutics Limited ADR (KZIA)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Oct 16, 2024

Kazia Therapeutics Stock Scheduled to Reverse Split on Monday, October 28th (NASDAQ:KZIA) - Defense World

Oct 16, 2024

Oct 02, 2024

Paxalisib shows promise in brain metastasis treatment - Investing.com

Oct 02, 2024

It makes sense and dollars to buy Kazia Therapeutics Limited ADR (KZIA) stock - SETE News

Oct 02, 2024

Market Recap: Kazia Therapeutics Limited ADR (KZIA)’s Positive Momentum, Closing at 0.43 - The Dwinnex

Oct 02, 2024

Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American - StockTitan

Oct 02, 2024

Oct 01, 2024